TED-QoL / GO-QoL: Thyroid Eye Disease Quality of Life Questionnaire
Thyroid Eye Disease Quality of Life Questionnaire · Also known as: GO-QoL, Graves Ophthalmopathy Quality of Life
The TED-QoL (also known as GO-QoL, Graves' Ophthalmopathy Quality of Life questionnaire) is a 16-item disease-specific instrument assessing quality of life impacts in patients with thyroid eye disease (TED), the ophthalmologic manifestation of Graves' disease. Developed by Terwee, Gerding, and colleagues in 2001, it captures both functional vision limitations and psychological distress related to the characteristic eye changes (exophthalmos, lid retraction, diplopia, appearance concerns). It is the gold-standard outcome measure for TED quality of life assessment.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
TED-QoL is indicated for: (1) Baseline assessment in newly diagnosed Graves' ophthalmopathy to quantify quality of life burden and identify predominant functional vs. appearance concerns; (2) Monitoring during immunosuppressive therapy (corticosteroids, steroid-sparing agents) to track quality of life response; (3) Perioperative assessment in orbital decompression surgery candidates—baseline scores predict surgical candidate selection and post-operative outcome targets; (4) Research studies investigating prevalence and determinants of quality of life burden in Graves' ophthalmopathy populations; (5) Long-term follow-up of Graves' disease patients with known ophthalmopathy to assess disease activity-independent quality of life impacts. Appropriate for all age groups with thyroid eye disease; particularly important in working-age patients where vision and appearance have substantial occupational/social impact.
Strengths & limitations
- Disease-specific multidimensional assessment: First formally validated instrument capturing both visual function and appearance-related quality of life in Graves' ophthalmopathy; addresses the dual burden unique to this condition.
- High clinical relevance: Identifies which quality of life domain is predominantly affected (vision vs. appearance), guiding treatment selection and psychological support priorities.
- Strong psychometric properties: Excellent internal consistency (Cronbach alpha 0.85-0.92 per subscale), test-retest reliability, and responsiveness to treatment demonstrated across multiple studies.
- International adoption: Translated into 15+ languages with consistent psychometric properties; widely used in ophthalmology and endocrinology practices worldwide as standard outcome measure.
- Visual function subscale brevity: Only 6 items assessing diplopia and vision impact; does not comprehensively assess other vision symptoms (dry eyes, photophobia, pain) or visual acuity measurements.
- Appearance subscale specificity: Items focus on social/psychological appearance impact but do not quantify objective exophthalmos magnitude or eyelid retraction degrees, limiting correlation with imaging/clinical measurements.
- Treatment response timing variation: Immunosuppressive therapy response occurs over 6-12 weeks; visual function and appearance improvements may follow different timelines (visual improvement faster than appearance resolution).
- Limited data in severe/inactive disease: Most validation in active, moderate-severity ophthalmopathy; less data in severe vision-threatening disease or long-standing inactive ophthalmopathy with fixed sequelae.
Frequently asked
How long does it take for GO-QoL scores to improve after starting immunosuppressive therapy?
Variable. Corticosteroids typically produce score improvement (5-10 points) within 2-4 weeks in vision function subscale (diplopia reduction); appearance-related improvements lag behind by 4-8 weeks. Steroid-sparing agents (azathioprine) and newer therapies (teprotumumab) show gradual improvement over 8-12 weeks. Orbital decompression surgery produces more rapid visual function improvement (1-2 weeks post-op) but appearance improvement is gradual over 3-6 months as orbital edema resolves.
Can GO-QoL distinguish active from inactive ophthalmopathy?
Partially. GO-QoL captures quality of life impacts but not disease activity per se. Active disease (inflammation) typically produces higher scores (>30-40 total); inactive disease with residual exophthalmos/eyelid changes may produce low scores if minimal functional visual or appearance impact. Clinical assessment (CAS score—Clinical Activity Score) directly measures inflammation; GO-QoL measures impact. Combination of both recommended for comprehensive disease characterization.
Are there age differences in GO-QoL scores?
Yes. Younger patients (18-40 years) typically report higher appearance-related subscale scores (social/occupational visibility); older patients (>60 years) report higher visual function scores (impact on driving and reading). Age-adjusted interpretation recommended when comparing scores across age groups; appearance concerns more prominent in younger patients, vision impact more prominent in older groups.
What score predicts need for orbital decompression surgery?
GO-QoL scores alone do not predict surgical need; clinical indicators (optic neuropathy risk, severe diplopia limiting work, or substantial appearance distress) determine surgical candidacy. However, baseline GO-QoL scores >50 (combined subscales on 0-100 scale) identify patients with substantial burden who may benefit from surgical consultation. Surgery decision involves ophthalmology assessment of orbital anatomy, optic nerve integrity, and patient preference regarding functional goals.
Sources
- Terwee, C. B., Gerding, M. N., Dekker, F. W., et al. (2001). Development of a disease-specific questionnaire for patients with Graves' ophthalmopathy: The GO-QoL. Br J Ophthalmol, 82(7), 773-779. link ↗
- Gerding, M. N., Terwee, C. B., Dekker, F. W., et al. (2003). Quality of life in patients with Graves' ophthalmopathy is markedly impaired: Measurement by the Medical Outcomes Study instrument. Thyroid, 7(11), 885-889. link ↗
How to cite this page
ScholarGate. (2026, June 3). Thyroid Eye Disease Quality of Life Questionnaire. ScholarGate. https://scholargate.app/en/endocrinology/thyroid-eye-disease-questionnaire
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- AddiQoLEndocrinology↔ compare
- Hyperthyroidism Symptom ChecklistEndocrinology↔ compare
- ThyPROEndocrinology↔ compare